Immunovant Inc

Immunovant Inc

IMVT

Get informed when a big investor buys or sells

+ Follow
Market Cap$9.16B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Immunovant IncImmunovant Inc-15.7--73%--
$40.00

Target Price by Analysts

9.7% downsideImmunovant Target Price DetailsTarget Price
$4.94

Current Fair Value

88.8% downside

Overvalued by 88.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$9.16 Billion
Enterprise Value$8.36 Billion
Dividend Yield$- (-)
Earnings per Share$-2.77
Beta0.81
Outstanding Shares205,545,373

Return

Return on Equity-73.19%ROE
Return on Assets-63.13%
Return on Invested Capital-60.45%

Valuation & Multiples

P/E Ratio-15.73P/E Ratio
PEG-58.19PEG
Price to Sales-Price to Sales
Price to Book Ratio14.77Price to Book Ratio
Enterprise Value to Revenue1178.33
Enterprise Value to EBIT-18.81
Enterprise Value to Net Income-16
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-0.60
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Next Earnings Call

Expected Date
November 9, 2026
EPS Estimate
$-0.69
Average shareholder expectation
Revenue Estimate
$7.09 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.1536 4.90%
Total Calls1,801,100 28.30%
Total Puts276,600 5.25%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %54.47% 6.15%
Total Invested$4.27B 55.57%
Investors Holding235 9.00%

ESG Score

No data

About Immunovant Inc